Early Access Programmes

Reimbursed early access programs

In the dynamic field of early access programmes, Justin Stindt Consultants emerges as a key consulting agency. Our experts specialize in Pharma, Biotech, and Medtech market entry, providing essential guidance for navigating these complex processes. As a global consulting firm, we offer specialized knowledge and strategic insights for successful market access.
Our team of specialists serves as dedicated partners in your journey, ensuring informed decisions in early product introductions both via reimbursed early access programs such as AAC/AAP in France or compassionate use programs in other markets. This international agency is recognized for its tailored approach in the healthcare sector, supporting clients through every step of the early access programme.
At Justin Stindt Consultants, we prioritize efficient and effective market entry, leveraging our expertise to guide your innovative treatments swiftly to the market.

CLIENT TESTIMONIALS

We have been fortunate to have Justin and his team support the Market Access and Pricing function at Astellas on many occasions. We have engaged them to work with us on several Pricing & Reimbursement strategy and Due Diligence projects. The clear and focused insights provided from this work were instrumental in defining our value and price strategies and informed our decision making. We are pleased to have Justin Stindt Consulting as a key partner supporting our Market Access / Pricing & Reimbursement effort.

Mig Sleeper

VP MAx&P Astellas

Justin and his team have been instrumental in gaining patient access and reimbursement for our drug in a number of EU countries. Through Justin’s expertise and his extensive network across the EU, he has also been able to apply the appropriate skills and knowledge to select EU countries where reimbursement is feasible. Ultimately, Justin’s work has enabled patients with a serious, rare disease to receive access to a life extending treatment while establishing a competitive price and gaining reimbursement for the company.

Eldon Mayer

Chief Commercial Officer Eiger Biopharmaceuticals

Justin Stindt Consulting is a trusted expert in Market access strategies across Europe. I worked with the Justin Stindt Consulting team on a couple of projects from early access of innovative drugs to effective access processes: HTA, Value and pricing. I appreciate their level of expertise, high quality of deliverables, reliability and dedication to the assigned projects.

Antoine Bassel Amer

Senior VP Europe Indivior

GLOBAL PRICING & REIMBURSEMENT

PRICING & REIMBURSEMENT SUBMISSIONS

PAYER & HTA ENGAGEMENT

GLOBAL PRICING & REIMBURSEMENT

PRICING & REIMBURSEMENT SUBMISSION

PAYER & HTA ENGAGEMENT

Early Access Programmes

Early Access Programmes Germany

Early Access Programmes Italy

Early Access Programmes France

CLIENT TESTIMONIALS

Pharma Market Access Agency

Contact Our Company

News

Introducing the Joint Clinical Assessment (JCA) in the EU: Aiming to Enhance Access to Innovative Therapies but Risking to Duplicate HTA for the Industry

Pricing and Reimbursement France – Securing Early Reimbursement Through the Early Access Programs